Name: Late stage assay provider results from the probe development effort to identify inhibitors of PME-1: fluorescence-based dose response cell-based gel-based competitive Activity-Based Protein Profiling (ABPP) inhibition of ABHD10. ..more
Target
BioActive Compound: 1
Depositor Specified Assays
Show more |
| AID | Name | Type | Probe | Comment |
|---|---|---|---|---|
| 2130 | Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of Protein Phosphatase Methylesterase 1 (PME-1). | screening | Primary screen (PME-1 inhibitors) | |
| 2143 | Summary of probe development efforts to identify inhibitors of Protein Phosphatase Methylesterase 1 (PME-1). | summary | 3 | Summary (PME-1 inhibitors) |
| 2174 | Counterscreen for PME1 inhibitors: fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of lysophospholipase 1 (LYPLA1). | screening | Counterscreen (LYPLA1 inhibitors) | |
| 2171 | Fluorescence polarization-based biochemical high throughput confirmation assay for inhibitors of Protein Phosphatase Methylesterase 1 (PME-1). | screening | Confirmation assay (PME-1 inhibitors) | |
| 2177 | Counterscreen for PME1 inhibitors: fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of lysophospholipase 2 (LYPLA2). | screening | Counterscreen (LYPLA2 inhibitors) | |
| 2232 | Counterscreen for PME1 inhibitors: fluorescence polarization-based biochemical high throughput confirmation assay to identify inhibitors of lysophospholipase 2 (LYPLA2). | screening | Counterscreen confirmation (LYPLA2 inhibitors) | |
| 2233 | Counterscreen for PME1 inhibitors: fluorescence polarization-based biochemical high throughput confirmation assay for inhibitors of lysophospholipase 1 (LYPLA1). | screening | Counterscreen confirmation (LYPLA1 inhibitors) | |
| 2291 | Fluorescence polarization-based Maybridge primary biochemical high throughput screening assay to identify inhibitors of Protein Phosphatase Methylesterase 1 (PME-1). | screening | Primary screen (PME-1 inhibitors, Maybridge Library) | |
| 2363 | Late stage results from the probe development effort to identify inhibitors of the protein methylesterase PME-1: Inhibition of PME-1-mediated demethylation of PP2a | screening | MOA assay (Demethylation of PP2a) | |
| 2365 | Late stage results from the probe development effort to identify inhibitors of the protein methylesterase PME-1: Luminescence-based counterscreen assay to identify cytotoxic compounds | confirmatory | Counterscreen (Cytotoxicity HEC 293T) | |
| 2366 | Late stage results from the probe development effort to identify inhibitors of the protein methylesterase PME-1: Gel-based Activity-Based Protein Profiling (ABPP) IC50 | confirmatory | ABPP dose response screen (PME-1 inhibitors) | |
| 2368 | Late stage results from the probe development effort to identify inhibitors of the protein methylesterase PME-1: Gel-based Activity-Based Protein Profiling (ABPP) Gel Filtration Assay | screening | MOA assay (PME-1 inhibitors, gel filtration assay) | |
| 2369 | Late stage results from the probe development effort to identify inhibitors of the protein methylesterase PME-1: Gel-based Activity-Based Protein Profiling (ABPP) Inhibition | screening | ABPP screen (PME-1 inhibitors) | |
| 2371 | Late stage results from the probe development effort to identify inhibitors of the protein methylesterase PME-1: Gel-based Activity-Based Protein Profiling (ABPP) IC50: Purified enzyme | confirmatory | ABPP dose response screen (PME-1 inhibitors, purified enzyme) | |
| 463090 | Late stage assay provider results from the probe development effort to identify inhibitors of Protein Phosphatase Methylesterase 1 (PME-1): LC-MS/MS assay to assess binding of compounds to active site | other | 1 | MOA assay (PME-1 inhibitors, LC-MS assay) |
| 463091 | Late stage assay provider results from the probe development effort to identify inhibitors of Protein Phosphatase Methylesterase 1 (PME-1): luminescence-based biochemical dose response assay to determine cytotoxicity of inhibitor compounds | confirmatory | Counterscreen (Cytotoxicity HeLa) | |
| 463146 | Late stage assay provider results from the probe development effort to identify inhibitors of protein phosphatase methylesterase 1 (PME-1): Fluorescence-based biochemical gel-based ABPP | other | ABPP profiling (PME1 inhibitors in singlicate) | |
| 463149 | Late stage assay provider results from the probe development effort to identify inhibitors of PME-1: Fluorescence-based biochemical gel-based ABPP inhibition and selectivity | other | ABPP profiling (PME1 inhibition and selectivity in singlicate) | |
| 463131 | Late stage assay provider results from the probe development effort to identify inhibitors of protein phosphatase methylesterase 1 (PME-1): fluorescence-based cell-based inhibition | screening | ABPP profiling (PME1 inhibitors in singlicate) | |
| 463130 | Late stage assay provider results from the probe development effort to identify inhibitors of protein phosphatase methylesterase 1 (PME-1): Gel-based Activity-Based Protein Profiling (ABPP) IC50 Set 1 | confirmatory | ABPP profiling dose response (PME1 inhibitors in triplicate) | |
| 463124 | Late stage assay provider results from the probe development effort to identify inhibitors of protein phosphatase methylesterase 1 (PME-1): Gel-based Activity-Based Protein Profiling (ABPP) IC50 Set 2 | confirmatory | ABPP profiling dose response (PME1 inhibitors in triplicate) | |
| 463132 | Late stage assay provider results from the probe development effort to identify inhibitors of protein phosphatase methylesterase 1 (PME-1): Inhibition of PME-1-mediated demethylation of PP2A | screening | MOA assay (PP2a demethylation) | |
| 588835 | Late stage assay provider results from the probe development effort to identify inhibitors of PME-1: fluorescence-based dose response cell-based gel-based competitive Activity-Based Protein Profiling (ABPP) ABHD10 selectivity assay | other | ||
| 602468 | Late stage assay provider results from the probe development effort to identify inhibitors of PME-1: fluorescence-based biochemical gel-based competitive Activity-Based Protein Profiling (ABPP) inhibition and selectivity among cysteine-reactive proteins | other | ||
| 602485 | Late stage assay provider results from the probe development effort to identify inhibitors of PME-1: fluorescence-based cell-based gel-based competitive Activity-Based Protein Profiling (ABPP) inhibition of ABHD10 in vivo | other |
Description:
Source (MLPCN Center Name): The Scripps Research Institute Molecular Screening Center (SRIMSC)
Center Affiliation: The Scripps Research Institute (TSRI)
Assay Provider: Benjamin Cravatt, TSRI
Network: Molecular Libraries Probe Production Centers Network (MLPCN)
Grant Proposal Number: 1 R01 CA132630
Grant Proposal PI: Benjamin Cravatt, TSRI
External Assay ID: ABHD10_INH_FLUO_GELBASEDABPP_3XIC50_INSITU
Name: Late stage assay provider results from the probe development effort to identify inhibitors of PME-1: fluorescence-based dose response cell-based gel-based competitive Activity-Based Protein Profiling (ABPP) inhibition of ABHD10.
Description:
Protein phosphatase methylesterase-1 (PME-1)-mediated methylesterification is thought to control the binding of different subunits to protein phosphatase 2A (PP2A) (1), which, along with protein phosphatase 1 (PP1), is responsible for > 90% of all serine/threonine phosphatase activity (2). PME-1 has also been identified as a protector of sustained ERK pathway activity in malignant gliomas (3), suggesting a link between cancer progression and PME-1-regulated methylesterification. A fluorescence-polarization activity-based protein profiling (fluopol-ABPP) HTS assay for PME-1 inhibitor discovery (AIDs 2130 and 2171) unveiled a phenomenal class of potent and selective inhibitors, the aza-beta lactams (ABLs). During medicinal chemistry campaign to refine ABL inhibitors for PME-1 (See Probe Report for ML174 on the NCBI bookshelf http://www.ncbi.nlm.nih.gov/books/NBK47352/), we observed that one of the common anti-targets of several ABL members was the uncharacterized serine hydrolase abhydrolase domain containing protein 10 (ABHD10). We have preliminary evidence that ABHD10 functions as a lipase in situ (unpublished); however is physiological substrates and biological role(s) have not yet been explored. A principle goal of post-genomic research is to elucidate the molecular and cellular roles of uncharacterized enzymes like ABHD10, work that requires selective chemical tools to inactivate enzyme activity in a controlled manner.
References:
1. Wu, J., Tolstykh, T., Lee, J., Boyd, K., Stock, J. B., Broach, J. R. (2000). Carboxyl methylation of the phosphoprotein phosphatase 2A catalytic subunit promotes its functional association with regulatory subunits in vivo. Embo J. 19, 5672-5681.
2. Oliver, C. J., Shenolikar, S. (1998). Physiologic importance of protein phosphatase inhibitors. Front. Biosci. 3, D961-972.
3. Puustinen, P., Junttila, M. R., Vanhatupa, S., Sablina, A. A., Hector, M. E., Teittinen, K., Raheem, O., Ketola, K., Lin, S., Kast, J., Haapasalo, H., Hahn, W. C., Westermarck, J. (2009). PME-1 protects extracellular signal-regulated kinase pathway activity from protein phosphatase 2A-mediated inactivation in human malignant glioma. Cancer Res. 69, 2870-2877.
Keywords:
late stage, late stage AID, assay provider, powders, dose response, abhdyrolase domain containing protein 10, ABHD10, uncharacterized, PME-1, protein phosphatase methylesterase 1, PPME-1, counterscreen, activity-based protein profiling, ABPP, inhibition, IC50, dose response, in situ, Neuro-2A, neuroblastoma cells, fluorophosphonate rhodamine, FP-Rh, inhibitor, selectivity, anti-targets, Scripps, Scripps Research Institute Molecular Screening Center, SRIMSC, Molecular Libraries Probe Production Centers Network, MLPCN
Center Affiliation: The Scripps Research Institute (TSRI)
Assay Provider: Benjamin Cravatt, TSRI
Network: Molecular Libraries Probe Production Centers Network (MLPCN)
Grant Proposal Number: 1 R01 CA132630
Grant Proposal PI: Benjamin Cravatt, TSRI
External Assay ID: ABHD10_INH_FLUO_GELBASEDABPP_3XIC50_INSITU
Name: Late stage assay provider results from the probe development effort to identify inhibitors of PME-1: fluorescence-based dose response cell-based gel-based competitive Activity-Based Protein Profiling (ABPP) inhibition of ABHD10.
Description:
Protein phosphatase methylesterase-1 (PME-1)-mediated methylesterification is thought to control the binding of different subunits to protein phosphatase 2A (PP2A) (1), which, along with protein phosphatase 1 (PP1), is responsible for > 90% of all serine/threonine phosphatase activity (2). PME-1 has also been identified as a protector of sustained ERK pathway activity in malignant gliomas (3), suggesting a link between cancer progression and PME-1-regulated methylesterification. A fluorescence-polarization activity-based protein profiling (fluopol-ABPP) HTS assay for PME-1 inhibitor discovery (AIDs 2130 and 2171) unveiled a phenomenal class of potent and selective inhibitors, the aza-beta lactams (ABLs). During medicinal chemistry campaign to refine ABL inhibitors for PME-1 (See Probe Report for ML174 on the NCBI bookshelf http://www.ncbi.nlm.nih.gov/books/NBK47352/), we observed that one of the common anti-targets of several ABL members was the uncharacterized serine hydrolase abhydrolase domain containing protein 10 (ABHD10). We have preliminary evidence that ABHD10 functions as a lipase in situ (unpublished); however is physiological substrates and biological role(s) have not yet been explored. A principle goal of post-genomic research is to elucidate the molecular and cellular roles of uncharacterized enzymes like ABHD10, work that requires selective chemical tools to inactivate enzyme activity in a controlled manner.
References:
1. Wu, J., Tolstykh, T., Lee, J., Boyd, K., Stock, J. B., Broach, J. R. (2000). Carboxyl methylation of the phosphoprotein phosphatase 2A catalytic subunit promotes its functional association with regulatory subunits in vivo. Embo J. 19, 5672-5681.
2. Oliver, C. J., Shenolikar, S. (1998). Physiologic importance of protein phosphatase inhibitors. Front. Biosci. 3, D961-972.
3. Puustinen, P., Junttila, M. R., Vanhatupa, S., Sablina, A. A., Hector, M. E., Teittinen, K., Raheem, O., Ketola, K., Lin, S., Kast, J., Haapasalo, H., Hahn, W. C., Westermarck, J. (2009). PME-1 protects extracellular signal-regulated kinase pathway activity from protein phosphatase 2A-mediated inactivation in human malignant glioma. Cancer Res. 69, 2870-2877.
Keywords:
late stage, late stage AID, assay provider, powders, dose response, abhdyrolase domain containing protein 10, ABHD10, uncharacterized, PME-1, protein phosphatase methylesterase 1, PPME-1, counterscreen, activity-based protein profiling, ABPP, inhibition, IC50, dose response, in situ, Neuro-2A, neuroblastoma cells, fluorophosphonate rhodamine, FP-Rh, inhibitor, selectivity, anti-targets, Scripps, Scripps Research Institute Molecular Screening Center, SRIMSC, Molecular Libraries Probe Production Centers Network, MLPCN
Protocol
Assay Overview:
The purpose of this assay is to determine the IC50 values of powder samples of test compounds for ABHD10 inhibition in situ. In this assay, cultured cells are incubated with test compound. Cells are harvested, homogenized, and reacted with a rhodamine-conjugated fluorophosphonate (FP-Rh) activity-based probe. The reaction products are separated by SDS-PAGE and visualized in-gel using a flatbed fluorescence scanner. The percentage activity remaining is determined by measuring the integrated optical density of the bands. As designed, test compounds that act as ABHD10 inhibitors will prevent enzyme-probe interactions, thereby decreasing the proportion of bound fluorescent probe, giving lower fluorescence intensity in the band in the gel.
Protocol Summary:
Cultured Neuro-2A murine neuroblastoma cells in serum-free DMEM medium (1 mL total volume) were treated with DMSO or test compound (10 uL of a 100x stock in DMSO) for 2 hours at 37 C. Cells were washed with DPBS, harvested, and resuspended in DPBS (1 mL). Centrifugation (1000 x g, 5 minutes) provided a cell pellet which was resuspended in DPBS (200 uL) and homogenized by sonication. The protein concentration was adjusted to 1 mg/mL with DPBS. FP-Rh (1 uL of 50x stock in DMSO) was added to a final concentration of 1 uM in 50 uL total reaction volume. The reaction was incubated for 30 minutes at 25 C, quenched with 4x SDS-PAGE loading buffer, separated by SDS-PAGE and visualized by in-gel fluorescent scanning. The percentage activity remaining was determined by measuring the integrated optical density of the ABHD10 band relative to a DMSO-only (no compound) control. IC50 values for inhibition of ABHD10 were determined from dose-response curves from three replicates at each inhibitor concentration (10 uM, 1 uM, 0.250 uM, 0.050 uM, 0.010 uM, 0.005 uM, and 0.001 uM).
The % inhibition was then calculated as follows:
%_Inhibition = ( 1 - ( IOD_Test_Compound - Median_IOD_Low_Control ) / ( Median_IOD_High_Control - Median_IOD_Low_Control ) ) * 100
Where:
Test_Compound is defined as ABHD10 treated with test compound.
High_Control is defined as ABHD10 treated with DMSO only (no compound).
Low_Control is defined as background in a blank region of the gel.
For each test compound, percent inhibition was plotted against the log of the compound concentration. A four parameter variable slope equation describing a sigmoidal dose-response curve was then fitted using GraphPad Prism (GraphPad Software Inc). The software-generated IC50 values are reported.
PubChem Activity Outcome:
Compounds with IC50 less than or equal to 0.5 uM were considered active. Compounds with IC50 greater than 0.5 uM were considered inactive.
The reported PubChem Activity Score has been normalized to 100% observed inhibition. Negative % inhibition values are reported as activity score zero.
The PubChem Activity Score range for active compounds is 100-100. There are no inactive compounds.
List of Reagents:
Neuro-2A murine cells (provided by Assay Provider)
FP-Rh (provided by the Assay Provider)
DMEM Medium (CellGro 10-017-CV)
DPBS (Cellgro 20-031-CV)
The purpose of this assay is to determine the IC50 values of powder samples of test compounds for ABHD10 inhibition in situ. In this assay, cultured cells are incubated with test compound. Cells are harvested, homogenized, and reacted with a rhodamine-conjugated fluorophosphonate (FP-Rh) activity-based probe. The reaction products are separated by SDS-PAGE and visualized in-gel using a flatbed fluorescence scanner. The percentage activity remaining is determined by measuring the integrated optical density of the bands. As designed, test compounds that act as ABHD10 inhibitors will prevent enzyme-probe interactions, thereby decreasing the proportion of bound fluorescent probe, giving lower fluorescence intensity in the band in the gel.
Protocol Summary:
Cultured Neuro-2A murine neuroblastoma cells in serum-free DMEM medium (1 mL total volume) were treated with DMSO or test compound (10 uL of a 100x stock in DMSO) for 2 hours at 37 C. Cells were washed with DPBS, harvested, and resuspended in DPBS (1 mL). Centrifugation (1000 x g, 5 minutes) provided a cell pellet which was resuspended in DPBS (200 uL) and homogenized by sonication. The protein concentration was adjusted to 1 mg/mL with DPBS. FP-Rh (1 uL of 50x stock in DMSO) was added to a final concentration of 1 uM in 50 uL total reaction volume. The reaction was incubated for 30 minutes at 25 C, quenched with 4x SDS-PAGE loading buffer, separated by SDS-PAGE and visualized by in-gel fluorescent scanning. The percentage activity remaining was determined by measuring the integrated optical density of the ABHD10 band relative to a DMSO-only (no compound) control. IC50 values for inhibition of ABHD10 were determined from dose-response curves from three replicates at each inhibitor concentration (10 uM, 1 uM, 0.250 uM, 0.050 uM, 0.010 uM, 0.005 uM, and 0.001 uM).
The % inhibition was then calculated as follows:
%_Inhibition = ( 1 - ( IOD_Test_Compound - Median_IOD_Low_Control ) / ( Median_IOD_High_Control - Median_IOD_Low_Control ) ) * 100
Where:
Test_Compound is defined as ABHD10 treated with test compound.
High_Control is defined as ABHD10 treated with DMSO only (no compound).
Low_Control is defined as background in a blank region of the gel.
For each test compound, percent inhibition was plotted against the log of the compound concentration. A four parameter variable slope equation describing a sigmoidal dose-response curve was then fitted using GraphPad Prism (GraphPad Software Inc). The software-generated IC50 values are reported.
PubChem Activity Outcome:
Compounds with IC50 less than or equal to 0.5 uM were considered active. Compounds with IC50 greater than 0.5 uM were considered inactive.
The reported PubChem Activity Score has been normalized to 100% observed inhibition. Negative % inhibition values are reported as activity score zero.
The PubChem Activity Score range for active compounds is 100-100. There are no inactive compounds.
List of Reagents:
Neuro-2A murine cells (provided by Assay Provider)
FP-Rh (provided by the Assay Provider)
DMEM Medium (CellGro 10-017-CV)
DPBS (Cellgro 20-031-CV)
Comment
This assay was performed by the assay provider with powder samples of synthetic compounds.
Categorized Comment
BAO: version: 1.4b1090
BAO: bioassay specification: assay stage: secondary: alternate confirmatory
BAO: bioassay specification: assay biosafety level: bsl1
BAO: assay format: biochemical format: protein format: protein complex format
BAO: bioassay specification: assay measurement type: endpoint assay
BAO: bioassay specification: assay readout content: assay readout method: regular screening
BAO: bioassay specification: assay readout content: content readout type: single readout
BAO: meta target: molecular target: protein target: enzyme: generic hydrolase
BAO: meta target detail: binding reporter specification: interaction: protein-small molecule
BAO: detection technology: fluorescence: fluorescence intensity
BAO: bioassay specification: assay stage: secondary: alternate confirmatory
BAO: bioassay specification: assay biosafety level: bsl1
BAO: assay format: biochemical format: protein format: protein complex format
BAO: bioassay specification: assay measurement type: endpoint assay
BAO: bioassay specification: assay readout content: assay readout method: regular screening
BAO: bioassay specification: assay readout content: content readout type: single readout
BAO: meta target: molecular target: protein target: enzyme: generic hydrolase
BAO: meta target detail: binding reporter specification: interaction: protein-small molecule
BAO: detection technology: fluorescence: fluorescence intensity
Result Definitions
| Show more |
| TID | Name | Description | Histogram | Type | Unit | |
|---|---|---|---|---|---|---|
| Outcome | The BioAssay activity outcome | Outcome | ||||
| Score | The BioAssay activity ranking score |  | Integer | |||
| 1 | IC50* | The average concentration at which 50 percent of the activity in the antagonist assay is observed; (IC50) shown in micromolar. | | Float | μM | |
| 2 | Inhibition at 10 uM [1] (10μM**) | The value for percent inhibition of endogenous mouse ABHD10 in situ at 10 uM compound concentration; replicate [1] | | Float | % | |
| 3 | Inhibition at 10 uM [2] (10μM**) | The value for percent inhibition of endogenous mouse ABHD10 in situ at 10 uM compound concentration; replicate [2] | | Float | % | |
| 4 | Inhibition at 10 uM [3] (10μM**) | The value for percent inhibition of endogenous mouse ABHD10 in situ at 10 uM compound concentration; replicate [3] | | Float | % | |
| 5 | Inhibition at 1 uM [1] (1μM**) | The value for percent inhibition of endogenous mouse ABHD10 in situ at 1 uM compound concentration; replicate [1] | | Float | % | |
| 6 | Inhibition at 1 uM [2] (1μM**) | The value for percent inhibition of endogenous mouse ABHD10 in situ at 1 uM compound concentration; replicate [2] | | Float | % | |
| 7 | Inhibition at 1 uM [3] (1μM**) | The value for percent inhibition of endogenous mouse ABHD10 in situ at 1 uM compound concentration; replicate [3] | | Float | % | |
| 8 | Inhibition at 0.25 uM [1] (0.25μM**) | The value for percent inhibition of endogenous mouse ABHD10 in situ at 0.25 uM compound concentration; replicate [1] | | Float | % | |
| 9 | Inhibition at 0.25 uM [2] (0.25μM**) | The value for percent inhibition of endogenous mouse ABHD10 in situ at 0.25 uM compound concentration; replicate [2] | | Float | % | |
| 10 | Inhibition at 0.25 uM [3] (0.25μM**) | The value for percent inhibition of endogenous mouse ABHD10 in situ at 0.25 uM compound concentration; replicate [3] | | Float | % | |
| 11 | Inhibition at 0.05 uM [1] (0.05μM**) | The value for percent inhibition of endogenous mouse ABHD10 in situ at 0.05 uM compound concentration; replicate [1] | | Float | % | |
| 12 | Inhibition at 0.05 uM [2] (0.05μM**) | The value for percent inhibition of endogenous mouse ABHD10 in situ at 0.05 uM compound concentration; replicate [2] | | Float | % | |
| 13 | Inhibition at 0.05 uM [3] (0.05μM**) | The value for percent inhibition of endogenous mouse ABHD10 in situ at 0.05 uM compound concentration; replicate [3] | | Float | % | |
| 14 | Inhibition at 0.01 uM [1] (0.01μM**) | The value for percent inhibition of endogenous mouse ABHD10 in situ at 0.01 uM compound concentration; replicate [1] | | Float | % | |
| 15 | Inhibition at 0.01 uM [2] (0.01μM**) | The value for percent inhibition of endogenous mouse ABHD10 in situ at 0.01 uM compound concentration; replicate [2] | | Float | % | |
| 16 | Inhibition at 0.01 uM [3] (0.01μM**) | The value for percent inhibition of endogenous mouse ABHD10 in situ at 0.01 uM compound concentration; replicate [3] | | Float | % | |
| 17 | Inhibition at 0.005 uM [1] (0.005μM**) | The value for percent inhibition of endogenous mouse ABHD10 in situ at 0.005 uM compound concentration; replicate [1] | | Float | % | |
| 18 | Inhibition at 0.005 uM [2] (0.005μM**) | The value for percent inhibition of endogenous mouse ABHD10 in situ at 0.005 uM compound concentration; replicate [2] | | Float | % | |
| 19 | Inhibition at 0.005 uM [3] (0.005μM**) | The value for percent inhibition of endogenous mouse ABHD10 in situ at 0.005 uM compound concentration; replicate [3] | | Float | % | |
| 20 | Inhibition at 0.001 uM [1] (0.001μM**) | The value for percent inhibition of endogenous mouse ABHD10 in situ at 0.001 uM compound concentration; replicate [1] | | Float | % | |
| 21 | Inhibition at 0.001 uM [2] (0.001μM**) | The value for percent inhibition of endogenous mouse ABHD10 in situ at 0.001 uM compound concentration; replicate [2] | | Float | % | |
| 22 | Inhibition at 0.001 uM [3] (0.001μM**) | The value for percent inhibition of endogenous mouse ABHD10 in situ at 0.001 uM compound concentration; replicate [3] | | Float | % |
* Activity Concentration. ** Test Concentration.
Additional Information
Grant Number: 1 R01 CA132630
Data Table (Concise)
Classification
PageFrom: